World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
75
Citations
23796
World Ranking
19055
National Ranking
806

Georg A. Bjarnason publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Georg A. Bjarnason sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 383 publications — 35th percentile

35% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Georg A. Bjarnason D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Georg A. Bjarnason sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 75 D-Index — 6th percentile

6% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Georg A. Bjarnason is affiliated with Sunnybrook Health Science Centre in Canada. Their research focuses primarily on renal cell carcinoma treatment, cancer genomics and diagnostics, and related oncological fields. Their body of work spans the disciplines of Medicine, Biochemistry, Genetics and Molecular Biology, with notable contributions in pulmonary and respiratory medicine, oncology, cancer research, molecular biology, and surgery.

Their main research topics include:

  • Renal cell carcinoma treatment
  • Cancer genomics and diagnostics
  • Renal and related cancers
  • Cancer immunotherapy and biomarkers
  • Bladder and urothelial cancer treatments
  • Economic and financial impacts of cancer
  • Pancreatic and hepatic oncology research

Georg A. Bjarnason has authored numerous publications in reputable venues. Their most frequent publication venues are:

  • Journal of Clinical Oncology
  • The Journal of Urology
  • Clinical Genitourinary Cancer
  • European Urology
  • Canadian Urological Association Journal

Their recent publications include:

  • Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma, 2021, Journal of Clinical Oncology
  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial, 2021, The Lancet
  • Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival, 2021, JAMA Network Open
  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma, 2023, Journal of Clinical Oncology
  • Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma, 2021, Journal of Clinical Oncology

Collaboration plays an important role in the scientist's work. Frequent co-authors include:

  • Lori Wood
  • Naveen S. Basappa
  • Aly-Khan A. Lalani
  • Rodney H. Breau
  • Frédéric Pouliot

Their research integrates both clinical and molecular study approaches, contributing to the understanding and treatment of renal and related cancers. The focus on immunotherapy and biomarkers is evident in several recent studies involving therapeutic interventions and survival outcomes.

Best Publications

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis

    John M.L. Ebos;Christina R. Lee;William Cruz-Munoz;Georg A. Bjarnason

  • Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma

    Toni K. Choueiri;Bernard Escudier;Thomas Powles;Paul N. Mainwaring

  • External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study

    Daniel Y.C. Heng;Wanling Xie;Meredith M. Regan;Lauren C. Harshman

  • Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

    Martin E Gore;Cezary Szczylik;Camillo Porta;Sergio Bracarda

  • Circadian expression of clock genes in human oral mucosa and skin: association with specific cell-cycle phases.

    Georg A. Bjarnason;Richard C.K. Jordan;Richard C.K. Jordan;Patricia A. Wood;Qi Li

  • Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

    Daniel Y.C. Heng;J. Connor Wells;Brian I. Rini;Benoit Beuselinck

  • Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma

    Thomas E. Hutson;Bernard Escudier;Emilio Esteban;Georg A. Bjarnason

  • The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study

    Jenny J. Ko;Wanling Xie;Nils Kroeger;Jae lyun Lee

  • Dovitinib versus sorafenib for third-line targeted treatment of patients with metastatic renal cell carcinoma: an open-label, randomised phase 3 trial

    Robert John Motzer;Camillo Porta;Nicholas J Vogelzang;Cora N Sternberg

  • Phase III Trial Comparing 4-Day Chronomodulated Therapy Versus 2-Day Conventional Delivery of Fluorouracil, Leucovorin, and Oxaliplatin As First-Line Chemotherapy of Metastatic Colorectal Cancer: The European Organisation for Research and Treatment of Cancer Chronotherapy Group

    Sylvie Giacchetti;Georg Bjarnason;Carlo Garufi;Dominique Genet

  • Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

    Nils Kroeger;Wanling Xie;Jae Lyn Lee;Georg A. Bjarnason

  • Impact of bone and liver metastases on patients with renal cell carcinoma treated with targeted therapy.

    Rana R. McKay;Nils Kroeger;Nils Kroeger;Wanling Xie;Jae Lyun Lee

  • Circadian Variation in the Expression of Cell-Cycle Proteins in Human Oral Epithelium

    Georg A. Bjarnason;Richard C.K. Jordan;Richard C.K. Jordan;Robert B. Sothern

  • Circadian rhythm in rest and activity: a biological correlate of quality of life and a predictor of survival in patients with metastatic colorectal cancer

    Pasquale F Innominato;Christian Focan;Thierry Gorlia;Thierry Moreau

  • miRNA Profiling for Clear Cell Renal Cell Carcinoma: Biomarker Discovery and Identification of Potential Controls and Consequences of miRNA Dysregulation

    Nicole M.A. White;Nicole M.A. White;Tian Tian Bao;Jörg Grigull;Youssef M. Youssef

  • Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma.

    David F McDermott;Jae-Lyun Lee;Marek Ziobro;Cristina Suarez

  • Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

    Laurence Albiges;Laurence Albiges;A. Ari Hakimi;Wanling Xie;Rana R. McKay

  • A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

    Sumanta K Pal;Catherine Tangen;Ian M Thompson;Naomi Balzer-Haas

  • Chronotherapy and the molecular clock: Clinical implications in oncology

    Pasquale F. Innominato;Francis A. Lévi;Georg A. Bjarnason

Frequent Co-Authors

Toni K. Choueiri
Toni K. Choueiri Harvard University
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Christian Kollmannsberger
Christian Kollmannsberger University of British Columbia
Sun Young Rha
Sun Young Rha Yonsei University
George M. Yousef
George M. Yousef University of Toronto
Ulka N. Vaishampayan
Ulka N. Vaishampayan University of Michigan–Ann Arbor
Antonio Finelli
Antonio Finelli University Health Network
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Michael A.S. Jewett
Michael A.S. Jewett University of Toronto
Camillo Porta
Camillo Porta University of Bari Aldo Moro

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring medicine in the USA opens doors to a wide range of healthcare careers, some of which can be pursued online. These online programs offer flexibility for students balancing work and family commitments.

For those interested in the technology side of healthcare, health information technology programs online provide critical skills for managing medical data and supporting patient care. If you’re detail-oriented and enjoy administrative work, medical billing and coding online courses can prepare you for essential roles within hospitals, clinics, and insurance companies.

Aspiring nurses have more options than ever before, with online nurse practitioner programs helping qualified candidates move into advanced clinical roles. There are also pathways to become a registered nurse through an nursing degree online, making it easier to start or progress a rewarding career in patient care.

These online healthcare degrees and certificates are shaping the future of medical education, broadening access to vital, in-demand professions across the country.

Best Scientists Citing Georg A. Bjarnason

Trending Scientists

Recently Published Articles